<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04882891</url>
  </required_header>
  <id_info>
    <org_study_id>ActiSEP. Part 2.</org_study_id>
    <nct_id>NCT04882891</nct_id>
  </id_info>
  <brief_title>Holter of Movement in Patients With Multiple Sclerosis in Uncontrolled Environment.</brief_title>
  <official_title>Holter of Movement in Patients With Multiple Sclerosis. Acti-SEP Study: Uncontrolled Environment.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Stéphanie Delstanche</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sysnav</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Hospitalier Universitaire de Liege</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier Régional de la Citadelle</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      ActiSEP is a multicentric academic study. Ambulant patients with multiple sclerosis may be&#xD;
      included on a voluntary basis. The investigators plan to include a group of approximately 80&#xD;
      patients with MS, fulfilling the McDonald's 2017 criteria, of whom 40 of them show a&#xD;
      progressive course according to the Lublin classification.&#xD;
&#xD;
      The investigators have planned two visits (at baseline and 1 year later). On both visits,&#xD;
      participants will perform few tests (timed 25-Foot Walk (T25-FW), 9-Hole Peg Test (9-HPG),&#xD;
      6-minutes walk test (6MWT), Berg balance scale) and will answer to some questionaires (Godin&#xD;
      Leisure Time Exercice Questionnaire, multiple sclerosis walking scale, modified fatigue&#xD;
      impact scale, Hospital Anxiety and Depression Scale) After each visit, participants will wear&#xD;
      Actimyo for three months in daily living.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 9, 2021</start_date>
  <completion_date type="Anticipated">February 15, 2024</completion_date>
  <primary_completion_date type="Anticipated">February 15, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>all patients undergo clinical evaluation and wear Actimyo device in daily living to assess their gait and its evolution.</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>95th centile of stride velocity</measure>
    <time_frame>1 year</time_frame>
    <description>95th centile of stride velocity obtained with a magneto-inertial sensor (Actimyo°) in real-life (meter per second).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>50th centile of stride velocity</measure>
    <time_frame>1 year</time_frame>
    <description>50th centile of stride velocity obtained with a magneto-inertial sensor (Actimyo°) in real-life (meter per second).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>95th centile of stride length</measure>
    <time_frame>1 year</time_frame>
    <description>95th centile of stride length obtained with a magneto-inertial sensor (Actimyo°) in real-life (meter).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>50th centile of stride length</measure>
    <time_frame>1 year</time_frame>
    <description>50th centile of stride length obtained with a magneto-inertial sensor (Actimyo°) in real-life (meter).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Stance phase time</measure>
    <time_frame>1 year</time_frame>
    <description>Stance time over full stride time for each foot obtained with a magneto-inertial sensor (Actimyo°) in real-life (percentage).</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>MS patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ambulant patients with multiple sclerosis</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Actimyo</intervention_name>
    <description>Actimyo° is an innovative device intended to be used in a home-based environment. It is composed of two watch-like sensors, each containing a magneto-inertial sensors that record the linear acceleration, the angular velocity, the magnetic field of the movement in all directions.The two watches can be worn as wristwatch or placed near the ankle.</description>
    <arm_group_label>MS patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Confirmed MS diagnosis,&#xD;
&#xD;
          -  Over 18 years old,&#xD;
&#xD;
          -  Ambulant patients,&#xD;
&#xD;
          -  Signed informed consent,&#xD;
&#xD;
          -  No clinical and / or radiological relapse within 3 months.&#xD;
&#xD;
          -  EDSS &lt; or = à 5,5,&#xD;
&#xD;
          -  Treated patient must be on a stable regimen dose and molecule for at least 2 month&#xD;
             prior to inclusion.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with excessive cognitive disorders, limiting the understanding of task or&#xD;
             with apparent communication difficulties hindering data collection.&#xD;
&#xD;
          -  Any other previous or present pathology having an impact on motor function.&#xD;
&#xD;
          -  Recent surgery or trauma (less than 6 months) in the upper or lower limbs&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Margaux Poleur, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHR Citadelle-CHU liège</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Laurie Medard</last_name>
    <phone>43218222</phone>
    <email>Laurie.Medard@chrcitadelle.be</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Liège</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurie Médard</last_name>
      <phone>43218222</phone>
      <phone_ext>0032</phone_ext>
      <email>Laurie.Medard@chrcitadelle.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHR Citadelle</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurie Médard</last_name>
      <phone>43218222</phone>
      <phone_ext>0032</phone_ext>
      <email>Laurie.Medard@chrcitadelle.be</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>March 11, 2021</study_first_submitted>
  <study_first_submitted_qc>May 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 12, 2021</study_first_posted>
  <last_update_submitted>May 11, 2021</last_update_submitted>
  <last_update_submitted_qc>May 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Centre Hospitalier Régional de la Citadelle</investigator_affiliation>
    <investigator_full_name>Dr. Stéphanie Delstanche</investigator_full_name>
    <investigator_title>Coordinator of reference center for neuromuscular diseases</investigator_title>
  </responsible_party>
  <keyword>Actimyo</keyword>
  <keyword>Accelerometry</keyword>
  <keyword>Home monitoring</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

